vTv Therapeutics completes Phase 1b study evaluating TTP399 for the treatment of T1D [Seeking Alpha]
vTv Therapeutics Inc. - Class A (VTVT)
Last vtv therapeutics inc. - class a earnings: 7/31 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.vtvtherapeutics.com
Company Research
Source: Seeking Alpha
vTv Therapeutics completes Phase 1b study evaluating TTP399 for the treatment of T1DvTv Therapeutics (NASDAQ:VTVT)announces the completion of Phase 1b clinical trial, Simplici-T1, the first part of an adaptive Phase 1b/2 study assessing the safety and tolerability of TTP399 in adult patients with type 1 diabetes (T1D). It is designed to evaluate TTP399 as an add-on to insulin therapy for type 1 diabetics.Results showed that TTP399 was well-tolerated and improved or maintained glycemic control while reducing or simplifying the insulin regimen. The Phase 2 portion will assess TTP39 over a 12-week treatment period.In a six-month Phase 2b clinical trial in patients with type 2 diabetes, TTP399 demonstrated significant reduction in HbA1c levels in all TTP399 dose groups compared with placebo.Shares are up4% premarket.Click to subscribe to real-time analytics on VTVTNow read:PLx Pharma beats by $0.05 »
Show less
Read more
Impact Snapshot
Event Time:
VTVT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VTVT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VTVT alerts
High impacting vTv Therapeutics Inc. - Class A news events
Weekly update
A roundup of the hottest topics
VTVT
News
- CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT [Yahoo! Finance]Yahoo! Finance
- CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMITPR Newswire
- vTv Therapeutics Inc. (NASDAQ: VTVT) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate UpdateGlobeNewswire
VTVT
Earnings
- 5/11/23 - Beat
VTVT
Sec Filings
- 4/10/24 - Form S-3
- 3/26/24 - Form 8-K
- 3/22/24 - Form SC
- VTVT's page on the SEC website